6 results about "Propionic acid derivatives" patented technology

The invention relates to extended-release formulations comprising substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5'-monophosphate- activated protein kinase (AMPK). The invention further relates to methods of treating a condition comprising administering an extended-release formulation comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

The invention relates to extended-release formulations comprising substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to methods of treating a condition comprising administering an extended-release formulation comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

The invention discloses a substituted pyridine propionic acid derivative and application thereof, and belongs to the field of chemical medicines. According to the pyridine propionic acid compound shown in the general formula (I) or the pharmaceutically acceptable salt of the pyridine propionic acid compound, in the compound, an A ring, a B ring and a C ring are independently selected from X1, X2, X3 and X4 are independently selected from N and CR, and at least one of X1, X2, X3 and X4 in the A ring is N. The compound disclosed by the invention has an excellent Lp (a) inhibiting effect and can be used as a medicine for reducing the Lp (a) level of plasma.

The present invention relates to a substituted indazole propionic acid derivative of formula (I), a pharmaceutically acceptable salt thereof, a tautomer or a pharmaceutically acceptable salt of the tautomer, which can activate adenosine 5 '-monophosphate activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising a substituted indazole propionic acid derivative that activates AMPK, a pharmaceutically acceptable salt thereof, a tautomer or a pharmaceutically acceptable salt of the tautomer, and at least one pharmaceutically acceptable excipient; and methods of treating conditions comprising administering a substituted indazole propionic acid derivative that activates AMPK, a pharmaceutically acceptable salt thereof, a tautomer, or a pharmaceutically acceptable salt of the tautomer.

Disclosed are a sodium phenylamino propionic acid derivative, a preparation method and application thereof. Specifically, disclosed is sodium 3-(4-(2-(9H-carbazol-9-yl)ethoxy)phenyl)-2-((2-(4-(4-(2-sodium carboxylate-2-((2-(4-fluorobenzoyl)phenyl)amino)ethyl)phenoxy)benzoyl)phenyl)amino)propanoate as shown in formula (I), a preparation method thereof and a use thereof for quality control of a raw material or preparation of siglitinide or a derivative thereof. In particular, the compound of formula (I) can be used as a control or standard for impurity / related substance inspection in siglitinide or a sodium salt drug.